November 8, 2016. We respectfully urge you to not advance the Senate’s Innovation for Healthier Americans bills or the House’s 21st Century Cures Act during the lame duck session of Congress. While the House version of the legislation provides additional funding for the National Institutes of Health (NIH), both the House and the Senate versions contain more controversial measures which would lower safety and approval standards for drugs and medical devices at the Food and Drug Administration (FDA).
Read More »On Health Policy
NCHR Testimony at FDA Risk Communication Advisory Committee – Public Forum to Discuss Strategic Plan for Risk Communication and Health Literacy
November 7, 2016. A major problem for FDA communication is how it has become increasingly promotional, rather than providing objective information about the products that the FDA regulates. Similarly, FDA needs to do a better job of preventing misleading information and inadequate explanations of risk in direct-to-consumer ads.
Read More »NCHR Letter to ACGME About Medical Residents’ Work Hours
October 13, 2016. We urge the ACGME to make patients’ lives a priority by keeping the first-year residents’ hours capped at 16 hours of continuous duty and to also apply the cap to all other residents.
Read More »NCHR Supports Increased User Fees for Generic Drugs
October 21, 2016. NCHR strongly supports increasing GDUFA and other user fees to improve FDA’s resources in order to enable the agency to fulfill its public health mission.
Read More »Public Health Advocates Support Tight FDA Restrictions on Pharmacy Compounded Drugs
October 11, 2016. NCHR strongly supports the draft guidance documents because they place tight restrictions on pharmacy compounding under sections 503A and 503B of the FD&C Act to prevent compounding drug products that are essentially copies of commercially available drug products and for those that are copies of approved drugs.
Read More »